MarketFriction

Venus Remedies Ltd

NSE VENUSREM · BSE 526953 · Pharmaceuticals
₹1,796.70 +0.03%
NSE close2026-10-01
52 week range428.00 - 2,044.30
Market cap₹2,284 Cr.
P/E19.7
ASM long-term Price band 5% Delivery 56.1%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales168143195109170177195137193180259179
Expenses15013117697163158166122162143196145
Operating Profit18121911818291531386334
OPM %11%8%10%10%4.5%10%15%11%16%21%24%19%
Other Income3242812732353
Interest000000000000
Depreciation676665566777
Profit before tax148177925311326336230
Tax %31%12%40%82%61%21%32%24%24%24%23%24%
Net Profit107111420211020264823
EPS in Rs7.445.127.860.912.6314.6615.717.1815.0619.1435.5417.18
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales407400372322335544597552596645766811
Expenses326349333289295490535492537577619645
Operating Profit81513933415462606069147166
OPM %20%13%11%10%12%10%10%11%10%11%19%20%
Other Income222-3-44381012261312
Interest383435251313000000
Depreciation424034343235343226232626
Profit before tax4-22-28-30-84936384572134152
Tax %52%-21%11%-4%24%-27%-12%30%36%37%23%
Net Profit2-17-31-29-106241272845103116
EPS in Rs1.49-13.84-24.87-23.15-8.1050.0530.4619.8821.3133.9076.9086.92
Dividend Payout %0%0%0%0%0%0%0%0%0%0%13%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth7%7%12%20%
Compounded Profit Growth50%20%53%149%
Stock Price CAGR31%31%89%296%
Return on Equity4%9%10%16%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital111112121212121313131313
Reserves445426376350320311388427447474548650
Borrowings32133531230729822051434241212
Other Liabilities64706582102100104979898153178
Total Liabilities841843765751733644556580601627716854
Fixed Assets444452406389364289262241216219229232
CWIP788066656525252526212651
Investments00000000201984238
Other Assets319310293297304330269314339368376333
Total Assets841843765751733644556580601627716854
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity68475931457813241373786156
Cash from Investing Activity-673-188-11-557-17-58-8-77-185
Cash from Financing Activity-1-46-44-39-35-73-162-9-1-1-1-3
Net Cash Flow-13-40-1-02714-22289-32
Free Cash Flow59464119357013241292469118
CFO/OP76%58%116%79%139%190%245%66%61%89%148%129%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days515543464333212451496449
Inventory Days19421922624628629612911813212597122
Days Payable4038485272777647565589107
Cash Conversion Cycle20423622124025725274951271207264
Working Capital Days54695425-17371821091188662
ROCE %6%5%2%1%1%2%8%8%8%9%11%21%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%
FIIs1.03%1.59%1.48%1.06%1.18%1.11%1.34%2.25%1.86%2.25%2.80%2.92%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.11%0.75%1.03%1.20%0.89%
Public57.21%56.65%56.76%57.17%57.06%57.13%56.90%55.89%55.62%54.95%54.24%54.44%
No. of Shareholders19,26719,56019,91319,61419,55719,77119,98219,30717,72518,60618,40321,905

Fundamentals

Market Cap₹ 2,284 Cr.
Current Price₹ 1,711
Stock P/E19.7
Book Value₹ 497
ROCE20.7 %
ROE15.6 %
Dividend Yield0.58 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)20%
Compounded Profit Growth (TTM)149%
Consolidated figures.
Valuation
Market capRs 2,402 Cr
Enterprise valueRs 2,384 Cr
P/E (TTM)20.67x
Price to book3.62x
Price to sales2.96x
EV / EBITDA13.40x
EV / EBIT15.72x
EV / sales2.94x
Price to cash flow15.42x
Earnings yield4.84%
Dividend yield0.56%
P/E, 3-year average11.60x
P/B, 3-year average1.09x
P/E, 5-year average10.37x
P/B, 5-year average0.91x
Profitability
Operating margin (excl. other income)19.22%
Operating margin (incl. other income)20.86%
EBITDA margin21.93%
Pre-tax margin18.69%
Net profit margin14.32%
Net margin, latest quarter12.84%
ROE16.79%
ROCE21.66%
ROA13.10%
ROE, 3-year average10.48%
ROCE, 3-year average14.50%
ROA, 3-year average8.16%
ROE, 5-year average9.41%
ROCE, 5-year average11.82%
ROA, 5-year average7.23%
ROIC (approx.)17.97%
Tax rate23.38%
Other income / net worth1.90%
Growth
Sales growth (latest year)18.80%
Profit growth (latest year)126.86%
Sales CAGR, 3 years11.53%
Sales CAGR, 5 years7.09%
Profit CAGR, 3 years56.98%
Profit CAGR, 5 years10.72%
Sales growth QoQ-31.05%
Profit growth QoQ-51.64%
Sales growth YoY (latest quarter)30.38%
Profit growth YoY (latest quarter)139.27%
Per share
EPS (TTM)Rs 86.92
EPS (latest year)Rs 76.90
EPS (latest quarter)Rs 17.18
EPS, 3-year averageRs 44.04
EPS, 5-year averageRs 36.49
Book value per shareRs 496.56
Sales per shareRs 606.92
Cash flow per shareRs 116.53
Free cash flow per shareRs 88.28
Dividend per share (latest year)Rs 10.00
Dividend per share, 3-year averageRs 10.00
Dividend per share, 5-year averageRs 10.00
Dividends
Dividend payout13.01%
Dividend payout, 3-year average13.01%
Dividend payout, 5-year average13.01%
Efficiency
Asset turnover0.90x
Fixed asset turnover3.31x
Inventory turnover3.22x
Inventory days113 days
Debtor days49 days
Debtors turnover7.42x
Creditor days107 days
Cash conversion cycle64 days
Working capital days62 days
Leverage
Total debtRs 12 Cr
Cash and bankRs 30 Cr
Net debtRs -17 Cr
Debt to equity0.02x
Net debt / EBITDA-0.10x
Interest coverage3791.25x
Current ratio (filing 2026-03-31)2.44x
Quick ratio (filing 2026-03-31)1.64x
Trade payables (filing 2026-03-31)Rs 113 Cr
Owners' fund to total sources77.75%
Debt to assets1.45%
Cash flow
Cash from Operating Activity (latest year)Rs 156 Cr
Cash from Investing Activity (latest year)Rs -185 Cr
Cash from Financing Activity (latest year)Rs -3 Cr
Net Cash Flow (latest year)Rs -32 Cr
Free cash flow (latest year)Rs 118 Cr
FCFE (approx.: FCF + change in debt)Rs 129 Cr
Cash from ops / profit, 5 years1.46x
Sales to cash flow4.92x
Statement figures
Net sales (TTM)Rs 811 Cr
Net sales (latest year)Rs 766 Cr
Sales (latest quarter)Rs 179 Cr
Operating profit excl. other income (latest year)Rs 147 Cr
Operating profit (latest quarter)Rs 34 Cr
Other income (TTM)Rs 12 Cr
EBITDA (TTM)Rs 178 Cr
PBDT (TTM)Rs 178 Cr
Profit before tax (TTM)Rs 152 Cr
Tax (latest year)Rs 31 Cr
Net profit (TTM)Rs 116 Cr
Net profit (latest year)Rs 103 Cr
Net profit (latest quarter)Rs 23 Cr
Depreciation (TTM)Rs 26 Cr
Depreciation (latest quarter)Rs 7 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 417 Cr
Total expenditure (latest year)Rs 619 Cr
Total income (latest year)Rs 779 Cr
Share capitalRs 13 Cr
ReservesRs 650 Cr
Shareholders' fundsRs 664 Cr
Total assetsRs 854 Cr
Net blockRs 232 Cr
Capital work in progressRs 51 Cr
InvestmentsRs 238 Cr
ReceivablesRs 103 Cr
InventoryRs 129 Cr
Other liabilitiesRs 178 Cr
Shares outstanding (crore)1.34
Ownership
Promoter holding41.76% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 20.7 is at the 97th percentile of its own 5.4-year range (median 12.8, low 5.0, high 23.8).
P/B 3.62 is at the 97th percentile (median 0.72).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodVENUSREMNifty 50Difference
1 week+10.6%-2.8% +13.4 pts
1 month+12.2%-6.8% +19.0 pts
3 months+4.4%-7.6% +12.0 pts
6 months+119.1%+0.4% +118.7 pts
1 year+302.6%-9.9% +312.5 pts
2 years+423.2%-13.6% +436.8 pts
3 years+609.2%+14.2% +595.0 pts
5 years+303.9%+27.9% +276.0 pts

Red flags

F-score 6 of 8
lookOn NSE surveillance On NSE surveillance: ASM long-term
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹179 Cr +30.7% vs Jun 2025. Net profit ₹23 Cr +130.0%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-08-07Dividend - Rs 10 Per Share
2024-09-13Annual General Meeting
2023-08-17Annual General Meeting
2022-08-11Annual General Meeting
2021-09-09 Annual General Meeting
2020-11-24 Annual General Meeting
2019-09-20 Annual General Meeting
2018-09-14 Annual General Meeting
2017-09-21 Annual General Meeting
2016-09-20 Annual General Meeting
2015-08-17 Annual General Meeting
2014-12-19Annual General Meeting
2013-09-23Annual General Meeting / Dividend - Rs 3/- Per Share
2012-09-20Annual General Meeting / Dividend Rs. 3/- Per Share
2011-09-22Annual General Meeting And Dividend Rs.3/- Per Share
2010-09-23Annual General Meeting And Dividend Rs.3/- Per Share
2009-09-17Agm/Div-Rs.3/- Per Share
2008-09-12Agm/Dividend - 40%
2007-09-18Agm/Dividend-30%
DateTypeWhat it says
2026-09-30UpdatesIntimation regarding change in Corporate Identification Number (CIN)..
2026-09-07UpdatesSocial Media Post on awareness on transfer of physical shares .
2026-08-21Shareholder meetingVoting Results and Scrutinizers report. Earlier submitted file was not machine readable.
2026-08-21Shareholder meetingVoting results.
2026-08-21Amendment to AOA/MOAThe Amendment to AOA/MOA of the company.
2026-08-20AppointmentAppointment of Dr. Gurminder Singh Bedi as Non- Executive Independent Director of the company w.e.f. May 26, 2026.
2026-08-20AppointmentAppointment of Dr. (Mrs.) Manu Chaudhary as Joint Managing Director of the company w.e.f. October 01, 2026.
2026-08-20AppointmentAppointment of Dr. (Mrs.) Savita Gupta as Non- Executive Independent Director of the company w.e.f. December 30, 2026.
2026-08-20AppointmentAppointment of Mr. Saransh Chaudhary as Executive Director of the company w.e.f. May 26, 2026.
2026-08-20Shareholder meetingProceedings of Annual General Meeting held on August 20, 2026
2026-07-24Shareholder meetingNotice of Annual General Meeting to be held on August 20, 2026, Annual report 2025-26 is also enclosed herewith.
2026-07-20Amendment to AOA/MOAThe Amendment to AOA/MOA of the company.
2026-07-20Board meeting outcomeOutcome of Board Meeting & Unaudited Financial Results as on 30th June 2026.
2026-07-18UpdatesSocial Media Post on KYC updation.
2026-07-07UpdatesSocial media post on awareness on physical shares. .
2026-06-16UpdatesSocial Media post to make shareholders aware to update their KYC.
2026-06-04UpdatesVenus Remedies Limited Secures Renewal of Prestigious DSIR in-house R&D Recognition.
2026-05-26UpdatesAdoption of MOA & AOA as per Companies Act 2013.
2026-05-26UpdatesDeclarartion of Dividend.
2026-05-26AppointmentAppointment of Gurminder Singh Bedi as Indepnedent Director of the company w.e.f. May 26, 2026.
2026-05-26AppointmentAppointment of Manu Chaudhary as Whole Time Director of the company w.e.f. October 01, 2026.
2026-05-26AppointmentAppointment of Savita Gupta as Injdependent Director of the company w.e.f. December 29, 2026.
2026-05-26AppointmentAppointment of Mr Saransh ChaudhARY as Whole Time Directors of the company w.e.f. May 26, 2026.
2026-05-26Record DateRecord date for the purpose of Dividend is 07-Aug-2026.
2026-05-26Board meeting outcomeOutcome of Board Meeting held on May 26, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2020-03-18NCLTState Bank of India Vs Venus Remedies Ltd.
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
Long Term Additional Surveillance Measure (Long Term ASM): stage 4
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03